Business

Sanofi acquires global rights to rovadicitinib from Sino Biopharmaceutical in up to USD 1.53b deal

Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (CTTQ), a subsidiary of Hong Kong-listed Sino Biopharmaceutical Limited (HKEX: 1177), has entered into an...

Sanofi Acquires Global Rights to Rovadicitinib in Up-to-USD 1.53 Billion Deal With Sino Biopharmaceutical

Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (CTTQ), a subsidiary of Hong Kong-listed Sino Biopharmaceutical Limited (HKEX: 1177), has entered into an exclusive license agreement with a fully owned subsidiary of Paris-based Sanofi S.A. (Euronext: SAN) for the global development, manufacturing, and commercialization of rovadicitinib, a first-in-class oral small-molecule JAK/ROCK dual-target inhibitor. Under the Sino Biopharmaceutical Sanofi license agreement, Sanofi receives an exclusive global license to the asset, which is already approved and marketed in China under the brand name Anxu. The deal is subject to customary closing conditions, including regulatory clearances.

The Chia Tai Tianqing Sanofi deal carries a total potential value of up to USD 1.53 billion. Sino Biopharmaceutical is eligible to receive an upfront payment of USD 135 million, plus development, regulatory, and sales milestone payments of up to USD 1.395 billion. Sanofi will also pay up to double-digit tiered royalties on annual net sales. The source announcement did not disclose the specific breakdown of milestones across development, regulatory, and commercial categories, nor did it detail royalty tier thresholds or the precise territorial treatment of China commercialization rights, though Sino Biopharmaceutical's existing Chinese marketing authorization suggests it retains domestic commercial rights.

Deal Context

Rovadicitinib is a dual inhibitor of the JAK/STAT and ROCK signaling pathways. By targeting JAK, the molecule suppresses inflammatory cytokine signaling from myeloid cells. Concurrent ROCK inhibition modulates STAT3/STAT5 phosphorylation, downregulating overactivated Th17 cells and enhancing regulatory T cell function to restore immune homeostasis. This dual mechanism produces synergistic anti-inflammatory and anti-fibrotic effects.

In February 2026, China's National Medical Products Administration (NMPA) approved rovadicitinib for the first-line treatment of adult patients with intermediate-2 or high-risk primary myelofibrosis (PMF), post-polycythemia vera myelofibrosis (PPV-MF), or post-essential thrombocythemia myelofibrosis (PET-MF). In chronic graft-versus-host disease (cGVHD), the molecule has advanced to Phase III in China, where it received Breakthrough Therapy Designation from the CDE in August 2025. In the US, rovadicitinib has been cleared to conduct Phase II clinical studies in cGVHD. Phase Ib/IIa data published in Blood demonstrated superior 12-month failure-free survival and enhanced responses in fibrosis-dominated organs compared to other approved therapies, along with potential to overcome ruxolitinib resistance.

The Sanofi exclusive license rovadicitinib transaction represents the first identified direct partnership between the two companies. For Sanofi, the deal extends a pattern of in-licensing from Chinese innovators, following an August 2022 collaboration with Innovent Biologics on oncology assets and a March 2022 agreement with Adagene valued at up to approximately USD 2.5 billion for masked antibody technology. Sanofi also acquired Kadmon Holdings in 2021, gaining belumosudil (Rezurock), an approved selective ROCK2 inhibitor for cGVHD. The addition of rovadicitinib, a JAK/ROCK inhibitor, complements belumosudil's ROCK-only mechanism in the same indication. For Sino Biopharmaceutical, the Sino Biopharmaceutical CTTQ partnership with a top-tier multinational represents its first major global out-licensing transaction of this scale.

The AllSci BriefSystematic R&D and deal news. Daily.

The rovadicitinib JAK ROCK inhibitor enters a competitive landscape shaped by several approved agents. In myelofibrosis, Incyte's ruxolitinib (Jakafi), a JAK1/JAK2 inhibitor licensed to Novartis for ex-US rights under a 2009 deal valued at USD 150 million upfront plus up to USD 1.065 billion in milestones, remains the standard of care. Bristol Myers Squibb markets fedratinib (Inrebic), a JAK2 inhibitor, and CTI BioPharma's pacritinib targets JAK2/FLT3 in patients with thrombocytopenia. In cGVHD specifically, Sanofi's own belumosudil and Incyte's ruxolitinib hold approvals.

Recent JAK-focused licensing activity includes Galapagos's April 2024 divestiture of European filgotinib (JAK1) commercial rights to Alfasigma for EUR 100 million upfront plus up to EUR 100 million in sales milestones, and Theravance Biopharma's December 2023 out-licensing of gut-selective pan-JAK inhibitor izencitinib to Zydus Lifesciences for USD 23.5 million upfront plus approximately USD 182 million in milestones.

Other molecules in active clinical development for overlapping indications include:

  • Ruxolitinib (Incyte/Novartis) — approved for myelofibrosis and cGVHD
  • Fedratinib (Bristol Myers Squibb) — approved for myelofibrosis
  • Pacritinib (CTI BioPharma) — approved for myelofibrosis with thrombocytopenia
  • Belumosudil (Sanofi/Kadmon) — approved ROCK2 inhibitor for cGVHD

No other dual JAK/ROCK inhibitor with comparable clinical-stage data has been publicly identified, supporting rovadicitinib's first-in-class designation in this combined mechanism category.


Spot something wrong? Report an issue with this article